Latest news
The Edges of Mayne Pharma explored - Wolters KluwerWolters Kluwer · Fri, 07 Aug 2026 10:43:34 GMTInside Mayne Pharma’s (ASX:MYX) Latest Price Move and What Healthcare Investors Are Watching - KalkineKalkine · Fri, 07 Aug 2026 08:05:00 GMTMYX:ASX Announcement - Mayne Pharma Bioshares Summit Presentation - 05 Aug 2026 - Market IndexMarket Index · Thu, 06 Aug 2026 03:08:29 GMTMYX:ASX Announcement - Non-Executive Director appointment - 05 Aug 2026 - Market IndexMarket Index · Thu, 06 Aug 2026 03:06:40 GMTMayne Pharma (ASX:MYX) Faces Board Pressure as Investors Push for Strategic Reset After Takeover Collapse - KalkineKalkine · Thu, 06 Aug 2026 02:36:00 GMTMayne Pharma Group Reports Lapse of 24,860 Performance Rights - KalkineKalkine · Wed, 05 Aug 2026 07:16:57 GMTMayne Pharma Group Issues 161,465 Ordinary Shares Following Performance Rights Conversion - KalkineKalkine · Wed, 05 Aug 2026 07:16:57 GMTMayne Pharma Group Announces Expiry of 24,860 Performance Rights Effective July 30, 2026 - Kalkine MediaKalkine Media · Wed, 05 Aug 2026 07:16:57 GMT